Wells Fargo analyst Tiago Fauth raised the firm’s price target on Liquidia to $23 from $20 and keeps an Overweight rating on the shares. The firm says that following a lengthy legal battle with United Therapeutics (UTHR), Liquidia (LQDA) received final FDA approval for Yutrepia in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Pricing and label are as expected, and focus shifts to the launch. Wells notes results in November of first full quarter of launch are the next key catalyst.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Strategic Launch and Market Potential of Yutrepia Justifies Buy Rating for Liquidia Technologies
- Liquidia price target raised to $37 from $29 at BTIG
- Liquidia price target raised to $31 from $27 at Jefferies
- Liquidia Technologies: Overcoming Legal Hurdles with Yutrepia’s FDA Approval and Positive Growth Outlook
- Liquidia price target raised to $25 from $22 at BofA